A U.S. claims-based study shows a roughly 50% reduction in childhood pneumonia hospitalisations since the introduction of PCV13, although gaps remain among children with medical complexities and for certain racial and income groups.
A large U.S. claims-based study suggests that childhood pneumonia hospitalizations have fallen sharply since routine use of the 13-valent pneumococcal conjugate vaccine, or PCV13, began more than a decade ago, even as important gaps in risk remain for children with medical complexity and for some racial and income groups.
Researchers writing in the journal Vaccines analysed more than 10 million children using Optum’s Clinformatics Data Mart database and found that all-cause hospitalised pneumonia rates dropped by roughly half across every age band after the 2010 PCV13 recommendation. Among children younger than 2 years, the rate fell from 410.2 to 177.0 per 100,000 person-years by the final study period. Declines were also seen in children aged 2 to 5 years and 6 to 17 years, with relative reductions of 51% and 52%, respectively.
The findings add to earlier evidence that pneumococcal conjugate vaccines have had broad effects beyond the targeted bacteria. Previous U.S. research has linked PCV introduction to major declines in invasive pneumococcal disease and in non-invasive pneumonia, including hospitalisation reductions in young children and benefits that extended to older adults through indirect protection. A separate Tennessee study found that all-cause pneumonia admissions fell among both Black and white children after PCV introduction, though some disparities persisted.
Even so, the new analysis shows that pneumonia burden has not been evenly shared away. Children with underlying medical conditions continued to have much higher rates than low-risk peers, and smaller but statistically significant differences remained by race and household income. The authors said the pattern is likely to reflect several factors, not vaccination alone, including changes in clinical practice and increased in-home services. Public health experts have also noted that current U.S. immunization guidance now uses PCV15 or PCV20 in childhood, with ACIP recommending a four-dose series and catch-up options for children who began with PCV13. The American Academy of Pediatrics continues to recommend routine pneumococcal vaccination for all infants and for older children with high-risk conditions, while research on pharmacists’ vaccine knowledge suggests more work is needed to improve counselling and recommendation rates.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
